Eli Lilly Climbs 1.8%, Trades at 29x Forward P/E Ahead of 124.6% EPS Surge
Eli Lilly shares climbed 1.82% on March 9 to $1,008.39, outpacing the S&P 500, but are down 6.41% over the past month compared with the Medical sector’s 3.46% decline. Analysts forecast April 30 earnings of $7.50 per share (+124.6% year-over-year) on revenue of $17.66 billion (+38.8%), while the stock trades at a 29x forward P/E and holds a PEG ratio of 1.17 versus sector averages.
1. Daily and Monthly Performance
Eli Lilly shares rose 1.82% on March 9 to close at $1,008.39, outpacing the S&P 500’s 0.83% gain. Despite today’s strength, the stock is down 6.41% over the past month, underperforming the Medical sector’s 3.46% decline and the S&P 500’s 2.65% drop.
2. Earnings Forecast
The company is set to report first-quarter results on April 30, with analysts expecting EPS of $7.50, up 124.6% year-over-year, and revenue of $17.66 billion, a 38.8% increase from the prior-year quarter. Full-year estimates stand at $34.16 per share (+41.1%) on $81.93 billion in revenue (+25.7%).
3. Valuation Ratios
Eli Lilly trades at a 29x forward P/E multiple, well above the Medical sector average of 15.83. The stock’s PEG ratio is 1.17, implying a premium growth valuation compared with the industry’s 2.24 average.
4. Analyst Rank and Industry Standing
The consensus EPS estimate for the quarter has inched up 0.24% over the past month, and the stock holds a Zacks Rank of #3 (Hold). The Large Cap Pharmaceuticals industry sits in the bottom 19% of all industries with a Zacks Industry Rank of 200.